Next Article in Journal
Pentavalent Antimonials: New Perspectives for Old Drugs
Next Article in Special Issue
Quinones as Key Intermediates in Natural Products Synthesis. Syntheses of Bioactive Xanthones from Hypericum perforatum
Previous Article in Journal
Ionic Liquids in Tribology
Previous Article in Special Issue
Brominated Thiophenes as Precursors in the Preparation of Brominated and Arylated Anthraquinones
Article Menu

Export Article

Open AccessArticle
Molecules 2009, 14(7), 2306-2316; doi:10.3390/molecules14072306

Synthesis and Antitumor Evaluation of Novel Bis-Triaziquone Derivatives

Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei, Taiwan
Department of Biochemistry, Taipei Medical University, 250 Wu-Hsin St. Taipei, Taiwan
College of Medicine, Fu-Jen Catholic University, 510 Chung Cheng Rd, Hsin-Chuang,Taipei Hsien 24205, Taiwan
Author to whom correspondence should be addressed.
Received: 30 April 2009 / Revised: 19 June 2009 / Accepted: 23 June 2009 / Published: 29 June 2009
View Full-Text   |   Download PDF [268 KB, uploaded 18 June 2014]   |  


Aziridine-containing compounds have been of interest as anticancer agents since late 1970s. The design, synthesis and study of triaziquone (TZQ) analogues with the aim of obtaining compounds with enhanced efficacy and reduced toxicity are an ongoing research effort in our group. A series of bis-type TZQ derivatives has been prepared and their cytotoxic activities were investigated. The cytotoxicity of these bis-type TZQ derivatives were tested on three cancer lines, including breast cancer (BC-M1), oral cancer (OEC-M1), larynx epidermal cancer (Hep2) and one normal skin fibroblast (SF). Most of these synthetic derivatives displayed significant cytotoxic activities against human carcinoma cell lines, but weak activities against SF. Among tested analogues the bis-type TZQ derivative 1a showed lethal effects on larynx epidermal carcinoma cells (Hep2), with an LC50 value of 2.02 mM, and also weak cytotoxic activity against SF cells with an LC50 value over 10 mM for 24 hr treatment. Comparing the viability of normal fibroblast cells treated with compound 1a and TZQ, the LC50 value of the latter was 2.52 mM, indicating more toxicity than compound 1a. This significantly decreased cytotoxicity of compound 1a towards normal SF cells, while still maintaining the anticancer activity towards Hep2 cells is an interesting feature. Among the seven compounds synthesized, compound 1c has similar toxicity effects on the three cancer cell lines and SF normal cells as the TZQ monomer.
Keywords: bioreductive compound; bis-triaziquone derivatives; cytotoxicity bioreductive compound; bis-triaziquone derivatives; cytotoxicity
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Huang, C.H.; Kuo, H.-S.; Liu, J.-W.; Lin, Y.-L. Synthesis and Antitumor Evaluation of Novel Bis-Triaziquone Derivatives. Molecules 2009, 14, 2306-2316.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top